A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Description

The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.

Study Start Date

July, 05 2017

Estimated Completion Date

June 2024

Interventions

  • Drug: Alectinib
  • Drug: Crizotinib

Study ID

Hoffmann-La Roche -- BO39694

Status

Recruiting

Trial ID

NCT03194893

Study Type

Interventional

Trial Phase

Phase 3

Enrollment Quota

200

Sponsor

Hoffmann-La Roche

Inclusion Criteria

  • Participants enrolled in a Roche-sponsored alectinib trial who are experiencing a clinical benefit from alectinib or crizotinib treatment at the time of discontinuation from the parent trial and for whom a switch to commercial supply is not feasible
  • Collected study termination data, including efficacy and safety data, as required by the parent study on the electronic Case Report Form (eCRF)
  • For women who are not postmenopausal (? 12 months of non?therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug
  • For men: agreement to remain abstinent or use a contraceptive method that results in a failure rate of < 1% per year during the treatment period and for at least 3 months after the last dose of study drug.

Exclusion Criteria

  • Evidence of lack of clinical benefit in parent trial during the screening phase of this rollover study
  • Permanent discontinuation of alectinib or crizotinib for any reason during the parent study or before first dose of study drug in the rollover study
  • Evidence of an adverse event for which the parent protocol stipulates permanent discontinuation
  • Pregnant or breastfeeding women
  • Ongoing serious adverse event that has not resolved to baseline level or Grade ?1 prior to first dose of study treatment in the rollover study
  • Treatment interruption for more than 21 days due to an adverse event since the last administration of alectinib or crizotinib in the parent trial. Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator
  • Administration of strong/potent cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days prior to the first dose of treatment on this study and while on treatment with crizotinib
  • Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures
  • these conditions should be discussed with the participant before trial entry

Gender

All

Ages

N/A

Accepts Healthy Volunteers

No

Study Locations and Contact Information (9)

Study Location Distance Name Phone Email
Massachusetts General Hospital Cancer Center - Boston, Massachusetts 2.8 miles None None None
Baptist Health Medical Group Oncology LLC - Miami, Florida 1,271.8 miles None None None
Baptist Health Medical Group Oncology LLC - Miami, Florida 1,271.8 miles None None None
Baptist Health Medical Group Oncology LLC - Miami, Florida 1,271.8 miles None None None
Baptist Health Medical Group Oncology LLC - Miami, Florida 1,271.8 miles None None None
Chao Family Comprehensive Cancer Center UC Irvine Medical Center - Orange, California 2,585.0 miles None None None
Chao Family Comprehensive Cancer Center UC Irvine Medical Center - Orange, California 2,585.0 miles None None None
Chao Family Comprehensive Cancer Center UC Irvine Medical Center - Orange, California 2,585.0 miles None None None
Chao Family Comprehensive Cancer Center UC Irvine Medical Center - Orange, California 2,585.0 miles None None None

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.